Respiratory syncytial virus: prospects for new and emerging therapeutics
- 14 June 2017
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 11 (8) , 609-615
Abstract
Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infections (LRTI) in infants, the elderly, and the immunocompromised. Although the development of a RSV vaccine has been a priority for >50 years, there is still no vaccine available. Treatment of RSV LRTI has remained mostly supportive, i.e. hydration and oxygenation. Palivizumab and ribavirin are the only options currently available for prevention and treatment of RSV infection, but evidence suggests that they are not fully effective. This creates a significant unmet medical need for new therapeutics for prevention and treatment of RSV worldwide. Areas covered: This article reviews the antiviral drugs and monoclonal antibodies (mAb) for RSV that are in different stages of clinical development. Expert commentary: Over the last 10 years, new antiviral drugs and mAb have shown clinical promise against RSV, and may become available in the coming years. Although the RSV fusion protein has been the most popular target for inhibitors and mAbs, new approaches targeting other viral proteins have shown promising results. To overcome the emergence of RSV escape mutants, combination antiviral therapy may be explored in the future.Keywords
This publication has 69 references indexed in Scilit:
- The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus InfectionJournal of Immunology Research, 2013
- Respiratory Syncytial Virus Entry Inhibitors Targeting the F ProteinViruses, 2013
- Inhibition of Human Respiratory Syncytial Virus Infectivity by a Dendrimeric Heparan Sulfate-Binding PeptideAntimicrobial Agents and Chemotherapy, 2012
- Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these yearsVirus Research, 2011
- Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing EpitopesJournal of Virology, 2011
- Surfactant proteins and respiratory syncytial virusThe Journal of Pediatrics, 2010
- Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit FusionJournal of Virology, 2010
- Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisThe Lancet, 2010
- A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virusProceedings of the National Academy of Sciences, 2010
- RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral StrategyAntimicrobial Agents and Chemotherapy, 2009